News headlines about Verona Pharma plc – American Depositary Share (NASDAQ:VRNA) have trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Verona Pharma plc – American Depositary Share earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.2953689022409 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
A number of analysts have recently commented on VRNA shares. Stifel Nicolaus set a $25.00 price target on Verona Pharma plc – American Depositary Share and gave the stock a “buy” rating in a research report on Friday, March 2nd. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price target on shares of Verona Pharma plc – American Depositary Share in a research report on Tuesday, February 13th. Finally, Berenberg Bank initiated coverage on Verona Pharma plc – American Depositary Share in a research report on Tuesday, February 20th. They issued a “buy” rating and a $30.00 target price for the company. One analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $25.67.
VRNA stock traded down $0.08 during midday trading on Wednesday, hitting $17.30. 1,344 shares of the stock traded hands, compared to its average volume of 6,607. Verona Pharma plc – American Depositary Share has a 12-month low of $10.44 and a 12-month high of $17.52.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by BBNS and is owned by of BBNS. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://baseballnewssource.com/2018/03/22/verona-pharma-plc-american-depositary-share-vrna-earning-somewhat-positive-news-coverage-analysis-finds/1925018.html.
Verona Pharma plc – American Depositary Share Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The companys lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.
Receive News & Ratings for Verona Pharma plc - American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma plc - American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.